Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT06127290
Recruiting Observational

HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia

NCT06127290 · tracked via the Priya Life Science Poland tracker
Sponsor
Euresist Network GEIE
Phase
Observational
Started
2021-12-01
Last updated
2025-02-27

Condition(s) studied

HIV-1-infection

Study summary

Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * naïve patients starting 2nd generation INSTI treatment * first line patients under 2nd generation INSTI treatment with either viral RNA sequence before therapy start, or PBMC available with PBMC sample date not more than 3 years from therapy start date (with reasonably sure history of no failure in the interval from therapy start date to PBMC sample date\]). Exclusion Criteria: * patients not having a signed informed consent for the EIDB data repository, if required by local/national legislation in order to have data in the common data repository. * patients not having Signed Informed consent for the present study, if required by local authorities iii) Persons aged \< 18 at baseline

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
University Hospital of Cologne Cologne Germany Recruiting
University Hospital of Siena Siena Italy Recruiting
Pomeranian Medical University Szczecin Szczecin Poland Recruiting
Karolinska Institutet Stockholm Sweden Recruiting

Other trials for the same condition

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events Active, not recruiting
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06127290 on ClinicalTrials.gov ↗ ← All trials in Poland